|
These are the research programs that our faculty are involved in:
Ambati, Jayakrishna, MD (Lab web site is located here.)
Blackburn,
Peter, MD
PEARSON PA, Blackburn PJ., Yunker JJ. A randomized, double-masked,
pilot study of the safety and efficacy of 0.5 µg/day and 0.2 µg/day Iluvienô (fluocinolone
acetonide intravitreal insert) 0.19 mg in subjects with macular edema secondary
to retinal vein occlusion (Study open for enrollment.)
Sponsor: Alimera
Capoor, Seema, MD,FRCOphth
Conklin, John, MD
Crutchfield, Barbara J., OD
Katz, Douglas, MD
Napier, Sharon, MD
Pearson, P. Andrew MD
PEARSON PA, Blackburn PJ., Yunker JJ. A randomized, double-masked, pilot
study of the safety and efficacy of 0.5 µg/day and 0.2 µg/day
Iluvienô (fluocinolone acetonide intravitreal insert) 0.19 mg in subjects
with macular edema secondary to retinal vein occlusion (Study open for
enrollment.)
Sponsor: Alimera
Research Treatment of Retina Cystoid Macular Edema or Subretinal Neovascular
Membrane Using Fluocinolone Acetomide Intravitreal Implants. (Closed for
enrollment.)
A Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety
and Efficacy of Retisert™, an Intravitreal Fluocinolone Acetonide
Implant, in the Treatment of Patients with Diabetic Macular Edema. (Closed
for enrollment.)
The Standard Care versus COrticosteriod for REtinal Vein Occlusion (SCORE)
Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal
Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular
Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal
Vein Occlusion.
Sponsor: NIH - The EMMES Corporation in Rockville, Maryland
(the Coordinating Center for this study) (Closed for
enrollment.)
Sanders, Sheila P., MD
Stevens, Julia L., MD
Van Meter, Woodford S., MD
|
